Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
Simvastatin, a new HMG-CoA-reductase inhibitor, was administered to 27 patients for a period of one year. This drug caused a sustained decrease in total plasma- and LDL-cholesterol. No development of cataracts could be observed during this one year follow-up.
Behrens-Baumann
W
W
Department of Ophthalmology and Medicine, University of Goettingen, FRG.
Morawietz
A
A
Thiery
J
J
Creutzfeldt
C
C
Seidel
D
D
D002386:Cataract / Q000139:chemically induced*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019821:Simvastatin
D008078:Cholesterol, LDL; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin